TCR² Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit


CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will participate in a fireside chat at the Jefferies Cell & Genetic Medicine Summit on Thursday, September 29 at 2:00PM E.T.

See the original post here:
TCR² Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit

Related Posts